Barclays
BCYC

Barclays’s Bicycle Therapeutics BCYC Stock Holding History

Barclays’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9K Buy
2,357
+1,795
+319% +$10.3K ﹤0.01% 4687
2025
Q4 		$3.98K Sell
562
-1,710
-75% -$12.6K ﹤0.01% 5001
2025
Q3 		$17.6K Sell
2,272
-1,204
-35% -$9.09K ﹤0.01% 4959
2025
Q2 		$24.2K Buy
3,476
+168
+5% +$1.34K ﹤0.01% 4824
2025
Q1 		$28.1K Buy
3,308
+696
+27% +$8.2K ﹤0.01% 4737
2024
Q4 		$36.6K Buy
2,612
+2,345
+878% +$50.3K ﹤0.01% 4821
2024
Q3 		$6.04K Buy
267
+183
+218% +$4.22K ﹤0.01% 5016
2024
Q2 		$1.7K Hold
84
– – ﹤0.01% 4657
2024
Q1 		$2.09K Sell
84
-14,948
-99% -$318K ﹤0.01% 4913
2023
Q4 		$272K Buy
15,032
+14,864
+8,848% +$246K ﹤0.01% 4272
2023
Q3 		$3.38K Buy
168
+84
+100% +$1.92K ﹤0.01% 4422
2023
Q2 		$2.14K Hold
84
– – ﹤0.01% 4319
2023
Q1 		$1.79K Buy
+84
New +$2.11K ﹤0.01% 4898
2022
Q2 		– Sell
-2,129
Closed -$93K – 5020
2022
Q1 		$93K Sell
2,129
-1,471
-41% -$68.7K ﹤0.01% 3816
2021
Q4 		$219K Sell
3,600
-2,522
-41% -$139K ﹤0.01% 3530
2021
Q3 		$255K Buy
6,122
+1,522
+33% +$53.2K ﹤0.01% 3495
2021
Q2 		$140K Sell
4,600
-15,900
-78% -$480K ﹤0.01% 3707
2021
Q1 		$612K Buy
+20,500
New +$529K ﹤0.01% 3072

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's BCYC Position: Q1 2026 in Review

Barclays increased its Bicycle Therapeutics (BCYC) stake by 319% in Q1 2026, buying an estimated $10.3K and bringing the position to 2,357 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4687.

Barclays first reported a position in BCYC in Q1 2021 and has held it in 18 quarters since. The position peaked at $612K in Q1 2021. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Barclays held 2,357 shares of Bicycle Therapeutics worth $10.9K as of Q1 2026.
  • Barclays bought 1,795 Bicycle Therapeutics shares in Q1 2026, an estimated $10.3K.
  • Bicycle Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4687 holding.
  • Barclays first reported a position in Bicycle Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • Barclays's Bicycle Therapeutics position peaked at $612K in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.